Skip to main content

Research Repository

Advanced Search

Outputs (59)

Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease (2023)
Journal Article
Grove, J. I., Lo, P. C., Shrine, N., Barwell, J., Wain, L. V., Tobin, M. D., Salter, A. M., Borkar, A. N., Cuevas-Ocaña, S., Bennett, N., John, C., Ntalla, I., Jones, G. E., Neal, C. P., Thomas, M. G., Kuht, H., Gupta, P., Vemala, V. M., Grant, A., Adewoye, A. B., …Aithal, G. P. (2023). Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease. JHEP Reports, 5(8), Article 100764. https://doi.org/10.1016/j.jhepr.2023.100764

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a complex trait with an estimated prevalence of 25% globally. We aimed to identify the genetic variant underlying a four-generation family with progressive NAFLD leading to cirrhosis, de... Read More about Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease.

Classifying the unclassifiable—a Delphi study to reach consensus on the fibrotic nature of diseases (2023)
Journal Article
Massen, G. M., Allen, R. J., Leavy, O. C., Selby, N. M., Aithal, G. P., Oliver, N., Parfrey, H., Wain, L. V., Jenkins, G., Stewart, I., & Quint, J. K. (2023). Classifying the unclassifiable—a Delphi study to reach consensus on the fibrotic nature of diseases. QJM: An International Journal of Medicine, 116(6), 429-435. https://doi.org/10.1093/qjmed/hcad050

BACKGROUND: Traditionally, clinical research has focused on individual fibrotic diseases or fibrosis in a particular organ. However, it is possible for people to have multiple fibrotic diseases. While multi-organ fibrosis may suggest shared pathogeni... Read More about Classifying the unclassifiable—a Delphi study to reach consensus on the fibrotic nature of diseases.

Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study (2023)
Journal Article
Lee, J., Westphal, M., Vali, Y., Boursier, J., Ostroff, R., Alexander, L., Chen, Y., Fournier, C., Geier, A., Francque, S., Wonders, K., Tiniakos, D., Bedossa, P., Allison, M., Papatheodoridis, G., Cortez-Pinto, H., Pais, R., Dufour, J.-F., Leeming, D. J., Harrison, S., …LITMUS investigators, L. I. (2023). Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study. Hepatology, 78(1), 258-271. https://doi.org/10.1097/HEP.0000000000000364

Background and Aims: Detecting NASH remains challenging, while at-risk NASH (steatohepatitis and F≥ 2) tends to progress and is of interest for drug development and clinical application. We developed prediction models by supervised machine learning t... Read More about Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.

Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study (2023)
Journal Article
Vali, Y., Lee, J., Boursier, J., Petta, S., Wonders, K., Tiniakos, D., Bedossa, P., Geier, A., Francque, S., Allison, M., Papatheodoridis, G., Cortez-Pinto, H., Pais, R., Dufour, J. F., Leeming, D. J., Harrison, S. A., Chen, Y., Cobbold, J. F., Pavlides, M., Holleboom, A. G., …Bossuyt, P. M. (2023). Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. The Lancet Gastroenterology & Hepatology, 8(8), 714-725. https://doi.org/10.1016/S2468-1253%2823%2900017-1

Background: The reference standard for detecting non-alcoholic steatohepatitis (NASH) and staging fibrosis—liver biopsy—is invasive and resource intensive. Non-invasive biomarkers are urgently needed, but few studies have compared these biomarkers in... Read More about Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (2023)
Journal Article
Pennisi, G., Enea, M., Falco, V., Aithal, G. P., Palaniyappan, N., Yilmaz, Y., Boursier, J., Cassinotto, C., de Lédinghen, V., Chan, W. K., Mahadeva, S., Eddowes, P., Newsome, P., Karlas, T., Wiegand, J., Wong, V. W.-S., Schattenberg, J. M., Labenz, C., Kim, W., Lee, M. S., …Petta, S. (2023). Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Hepatology, 78(1), 195-211. https://doi.org/10.1097/HEP.0000000000000351

Background and Aims: We evaluated the diagnostic accuracy of simple, noninvasive tests (NITs) in NAFLD patients with type 2 diabetes (T2D). Methods and Results: This was an individual patient data meta-analysis of 1780 patients with biopsy-proven NAF... Read More about Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.

Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans (2023)
Journal Article
Ravindra, K. C., Vaidya, V. S., Wang, Z., Federspiel, J. D., Virgen-Slane, R., Everley, R. A., Grove, J. I., Stephens, C., Ocana, M. F., Robles-Díaz, M., Isabel Lucena, M., Andrade, R. J., Atallah, E., Gerbes, A. L., Weber, S., Cortez-Pinto, H., Fowell, A. J., Hussaini, H., Bjornsson, E. S., Patel, J., …Ramaiah, S. K. (2023). Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans. Nature Communications, 14, Article 1215. https://doi.org/10.1038/s41467-023-36858-6

Diagnosis of drug-induced liver injury (DILI) and its distinction from other liver diseases are significant challenges in drug development and clinical practice. Here, we identify, confirm, and replicate the biomarker performance characteristics of c... Read More about Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans.

Serum Metabolome Analysis Identified Amino-Acid Metabolism Associated With Pain in People With Symptomatic Knee Osteoarthritis – A Cross-Sectional Study (2023)
Journal Article
Mehta, O., Vijay, A., Gohir, S. A., Kelly, T., Zhang, W., Doherty, M., Walsh, D. A., Aithal, G., & Valdes, A. M. (2023). Serum Metabolome Analysis Identified Amino-Acid Metabolism Associated With Pain in People With Symptomatic Knee Osteoarthritis – A Cross-Sectional Study. Journal of Pain, https://doi.org/10.1016/j.jpain.2023.02.023

Osteoarthritis (OA) is the most common arthritis affecting synovial joints such as knees and hips of millions of people globally. Usage-related joint pain and reduced function are the most common symptoms experienced by people with OA. To improve pai... Read More about Serum Metabolome Analysis Identified Amino-Acid Metabolism Associated With Pain in People With Symptomatic Knee Osteoarthritis – A Cross-Sectional Study.

Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma (2023)
Journal Article
Mosconi, C., O'Rourke, J., Kloeckner, R., Sturm, L., Golfieri, R., Celsa, C., Fateen, W., Odisio, B. C., Garanzini, E. M., Peck-Radosavljevic, M., Borghi, A., Ma, Y. T., Stoehr, F., Bettinger, D., Giuffrida, P., Aithal, G. P., Lin, Y.-M., Spreafico, C., Giampalma, E., Johnson, P., & Cucchetti, A. (2023). Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 46, 449-459. https://doi.org/10.1007/s00270-023-03375-4

Purpose
Textbook Outcome (TO) is inclusive of quality indicators and it not been provided for trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).

Materials and Methods
Data on treatment-naïve HCC patients receiving TACE... Read More about Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma.